

India's Intas Pharma signs supply agreement for Ranibizumab biosimilar in Middle East

05 April 2022 | News

Ranibizumab is indicated for the treatment of age-related macular degeneration, macular edema, diabetic retinopathy, etc.



India-based Intas Pharmaceuticals has signed an exclusive license and supply agreement with Axantia Holding, a leading pharmaceutical company in the Middle East operating through its pharmaceutical subsidiaries; Pharma International Pharmaceutical & Chemical Manufacturing Co and Med City Pharmaceutical Industries for Ranibizumab.

Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.

Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US.

Ranibizumab is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).